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Available online 17 August 2016Antiphospholipid antibodies (aPLs) can vary both immunologically and functionally, thus it is important to effec-
tively and correctly identify their presence when diagnosing antiphospholipid syndrome. Furthermore, since
many immunological/functional tests are necessary to measure aPLs, complete examinations are often not per-
formed in many cases due to signiﬁcant burden on the testing departments. To address this issue, we measured
aPLs deﬁned according to the classiﬁcation criteria (anticardiolipin antibody: aCL) IgG/IgM and anti-β2 glycopro-
tein I antibody (aβ2GPI) (IgG/IgM) aswell as non-criteria antibodies (aCL IgA, aβ2GPI IgA and aβ2GPI domain I), in
a cohort of 211 patients (61 APS, 140 disease controls and 10 healthy individuals). APLs were measured using a
fully automated chemiluminescent immunoassay instrument (BIO-FLASH®/ACL AcuStar®) and with conven-
tional ELISA tests. We demonstrated that both sensitivity and accuracy of diagnosis of aCL IgG and aβ2GPI IgG
were high, in agreement with the past reports.Whenmultiple aPLswere examined, the accuracy of diagnosis in-
creased. The proportion of APS patients that were positive for 2 or more types of aPLs (47/61, 77%) was higher
than that of patients with systemic lupus erythematosus (SLE)(3/37, 9%), those with non-SLE connective tissues
diseases (1/53,2%), those with other diseases or healthy volunteers. Based on these ﬁndings, it was concluded
that the fully automated chemiluminescent immunoassay instrument,which allows the simultaneous evaluation
of many types of aPLs, offers clear advantages for a more complete, more rapid and less labor-intensive alterna-
tive to running multiple ELISA and could help in better diagnosis for suspected APS patients.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Antiphospholipid syndrome [1] is a condition in which the antibody
group, collectively referred to as antiphospholipid antibodies (aPLs),
leads to autoimmune thrombosis and pregnancy complications. Recent-
ly, there has been a proposal to revise the Sapporo international classi-
ﬁcation criteria of APS, known as the Sapporo criteria-Sydney revision
[2]. APLs broadly refers to autoantibodies that bind to various phospho-
lipids or to plasma proteins after they combine to form phospholipid
complexes. However, not all types of these antibodies exhibit pathoge-
nicity. As antiphospholipid syndrome(APS)-related aPL, or aPL with
pathogenicity, anticardiolipin antibody (aCL) IgG/IgM, anti-β2 glycopro-
tein I (anti-β2GPI antibody [aβ2GPI]) IgG/IgM, and lupus anticoagulantEndocrinology and Nephrology,
15, Nishi 7, Kita-ku, Sapporo
. This is an open access article underhave been deﬁned, according to the classiﬁcation criteria [2]. It has
also been reported that in addition to IgG and IgM antibody isotypes,
IgA antibodies to aCL or aβ2GPI can be detected in some APS patients,
but the pathological importance of such ﬁndings remains unclear [3].
Furthermore, it has been reported that autoantibody to a speciﬁc part
(domain 1) of the β2GPI molecule correlated signiﬁcantly with APS
thrombosis (anti-β2GPI domain 1 antibody: aβ2GPI D1) [4].
TheAutomatedCoagulation Laboratory (ACL) Acustar (Instrumenta-
tion Laboratories, USA) is an instrument (also known as the BIO-FLASH
instrument) that allows quantitative measurement of autoantibodies
using a chemiluminescence immunoassay (CIA) that is gaining accep-
tance in clinical practice [5–7]. Paramagnetic beads are coated with
cardiolipin orβ2GPI and form the basis for themeasurement. After incu-
bation of themagnetic beads with blood(serum/plasma) samples, mag-
netic separation, and washing of the beads, a tracer is added. The tracer
consists of isoluminol-labelled anti-human IgG antibody or anti-human
IgM antibody which will bind to any antibodies captured on the beads.
Following another incubation, an agent is then added to inducethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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quantitative evaluation is made in relative light units (RLUs). RLU are
converted to chemiluminescent units (CU)/ml using an assay-speciﬁc
standard curve. The upper limit of normal (ULN) value is set at 20 CU/
ml for all assays, based on the 99th-percentile of healthy volunteers in
the USA.
In this study, we compared the diagnostic performance of BIO-
FLASH/ACL Acustar assays to ELISA versions of these assays on speci-
mens from a cohort of Japanese patients with collagenosis, including
APS.
2. Patients and methods
2.1. Patients
We selected 61 consecutive patients with APS (including 55 patients
with primary APS) from whom serum was preserved when they visited
the rheumatology outpatient department of Medicine II, Hokkaido Uni-
versity Hospital or the outpatient Department of Internal Medicine,
Health Sciences University of Hokkaido, from April 2005 to March 2013.
Control subjects were selected from patients who visited the medical fa-
cilities during the same period and consisted of 37 patients with systemic
lupus erythematosus (SLE) without complications of thrombotic/obstet-
ric events, 53 patients with non-SLE connective tissue diseases (CTD: in-
cluded 24 subjects with rheumatoid arthritis, 7 with scleroderma, 4
with myositis, 6 with vasculitis syndrome, 5 with Sjorgen's syndrome,
and 7 with other autoimmune diseases).
Non-autoimmune patients were also selected as a control. Sixteen pa-
tients who were diagnosed as non-CTD with APS mimicking disease
(non-autoimmune thrombosis, pregnancy complication) were included.
Additionally, 34 outpatients of Department of Gastroenterology and
Hepatology, HokkaidoUniversityHospital,whowere diagnosed as having
chronic virus hepatitis were selected. As previously reported, production
of the transient aPL is often related to infections [8]. Among them, the
chronic virus hepatitis are reported as prone to produce aPL [9,10].
Two hundred and one subjects in total were examined in addition to
10 healthy volunteers. There were no signiﬁcant differences between
the APS group and the other patient groups with respect to age and
sex. The diagnosis of antiphospholipid antibody syndrome was made
according to the Sydney revision of the Sapporo criteria [2] by the expert
rheumatologists.
2.2. Measurement of antiphospholipid antibody
After obtaining informed consent from each subject and explaining
the aim of this study, we measured aCL IgG/IgM, and aβ2GPI IgG/IgM in
the preserved serum samples using the QUANTA Flash Anti-phospholipid
Assay Panel (INOVA Diagnostics, USA.; APL CIA panel), and aCL IgG/IgM,
aβ2GPI IgG/IgMwith a home-made ELISA that was prepared using a stan-
dardized in-house protocol [11,12]. We also examined aCL IgA, aβ2GPI
IgA, and aβ2GPI D1 IgG, which have not been deﬁned in the classiﬁcation
criteria, using the APL CIA panel.
As noted above, the upper limit of normal (ULN) for each component
of the APL CIA panel was set at 20 CU/ml. As reported previously [13], the
cutoff values of the home-made ELISAs were set at 18.5 IgG phospholipid
units or higher for IgG aCL and 7.0 IgM phospholipid units or higher for
IgM aCL, based on the 99th percentile of 132 healthy control volunteers.
Furthermore, the cutoff value of aβ2GPI was set at 2.2 units/ml or higher
for IgG and 6.0 units/ml or higher for IgM.
2.3. Analysis methods
We measured the sensitivity, speciﬁcity, likelihood ratio, and odds
ratio of the each CIA-measured aPLs onAPS diagnosis. The gold standard
of the APS diagnosiswas the expert diagnosis of the rheumatologists ac-
cording to the Sapporo criteria Sydney revision. We used the Kruskal-Wallis test to the compare aPLs titers amongpatient groups. The concor-
dances of the ELISA- and CIA-measured aPLs were analyzed with the
Cohen's kappa test. We considered the differences as being statistically
signiﬁcantwhen the p values were 0.05 or lower. All analyseswere per-
formed using XLSTAT® (Addinsoft, France).3. Results
3.1. Measurements with the APL CIA panel
The range of measurement values for the entire cohort obtained with
theAPL CIA panelwas aCL IgG 177.9 (0 [minimum]–5955.7 [highest]) CU/
ml, aCL IgM 15.5 (0–678.4) CU/ml, aCL IgA 10.5 (0–267.7) CU/ml, aβ2GPI
IgG 755.6 (0–52,115.1) CU/ml, aβ2GPI IgM 21.12 (0–1471.3) CU/ml,
aβ2GPI IgA 13.8 (0–350.9) CU/ml, and aβ2GPI DI 3.6 (0–3843.7) CU/ml.
The proportions of positive ﬁndings for each antibody measurement
(20 CU/ml or higher) were 51/211 subjects (24.2%), 18/211 (8.5%), 22/
211 (10.4%), 59/211 (28.0%), 18/211 (8.5%), 22/211 (10.4%), and 30/211
(14.2%), respectively.
When comparing the antibody values between the APS, SLE, non-SLE
collagen diseases, other diseases, and hepatic disease groups using the
APL panel, the APS group exhibited signiﬁcantly higher titers than other
patient groups for all antibody tests (Fig. 1). The 10 healthy volunteers
were negative for all aPL tests with both the homemade ELISA and the
APL CIA panel.3.2. Measurement accuracy with the APL CIA panel
Table 1 presents the sensitivity, speciﬁcity, positive and negative like-
lihood ratios, odds ratio and probability of correct classiﬁcation of the APL
CIA panel in the diagnosis of APS. Thus, the sensitivities represent the
positive rates of each aPLs in APS patients and speciﬁcities represent the
negative rate of aPLs in non-APS patients. The APL CIA panel showed a
speciﬁcity of 90% or higher for all antibody tests. In contrast, the sensitiv-
ities for IgM aCL and IgM aβ2GPI in the diagnosis of APS were compara-
tively low (25.0% and 28.3%, respectively), as were those for IgA aCL and
IgA aβ2GPI (26.2% and 27.9%, respectively) (Table 1). The APL CIA panel
showed comparatively high probabilities for correct classiﬁcation; 0.86
for IgG aCL and IgG aβ2GPI. When examination was performed for aPL
alone, which was deﬁned according to the classﬁcation criteria, the ﬁnd-
ings for single positive cases in the APS group, were aCL IgG 3/61 subjects
(4.9%), aCL IgM 1/61 (1.6%), aβ2GPI IgG 4/61(6.6%), and aβ2GPI IgM 3/
61(4.9%).
The positivity for aCL IgA and aβ2GPI IgA was similar in all patients.
Additionally, all patients with positive IgA aCL and/or IgA aβ2GPI were
positive for at least two criteria-deﬁned aPLs.
Positivity for aβ2GPI D1 was observed in 50.8% (31/61) of the APS
patients and in none of the controls. Single positivity for aβ2GPI D1
was observed only in 1/61 APS patients.3.3. APL CIA panel and the homemade ELISA
Positivity and titers for the aPLs were compared between the APL CIA
panel and the homemade ELISA (Table 2).
When the concordance rates of positive/negative antibody related to
the APS diagnosis were compared between the APLCIA panel and con-
ventional tests, it was found that the κ valuewas 0.55 or higher for indi-
vidual test items, suggesting that homologywith conventional testswas
fair (Table 3).
Similar results were conﬁrmed when the data of patients with
collagenosis (patients with APS, SLE, and non-SLE) and patients who
visited the rheumatology outpatient department (patients with and
without collagen diseases who visited the rheumatology outpatient de-
partment) were used as the test cohort.
Fig. 1. Antiphospholipid antibody values calculated for individual patient groups using the APL CIA panel. We measured aCL IgG(A), aCL IgM(B), aβ2GPI IgG(C), and aβ2GPI IgM(D) using
the APL CIA panel for patients with antiphospholipid antibody syndrome [1], systemic lupus erythematosus (SLE), non-SLE collagen disease (collagen) who visited the rheumatology
outpatient department (other), and gastrointestinal disease (chronic virus hepatitis; hepatitis). The vertical axis shows the individual antibody values (unit: CU/ml). The APS groups
exhibited higher values for all antiphospholipid antibodies (p b 0.0001, Kruskal-Wallis test) compared with the other groups. The data of aCL IgG, aCL IgM, aβ2GPI IgG, and aβ2GPI IgM
are plotted with 6000 CU/ml, 100 CU/ml, 12,000 IU/ml, and 1000 CU/ml used as the upper limits, respectively, and the data that showed higher titers are also plotted as the upper limit.
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The speciﬁcities for APS diagnosis were elevated and the sensitiv-
ities or probabilities of classiﬁcation declined as the number of posi-
tive criteria-deﬁned aPLs was increased in the APL panel analysis.
The sensitivity and/or the probability classiﬁcation of a diagnosis of
APS in patients with more than one positive criteria-deﬁned aPL
was better than that of patients only a single speciﬁc aPL. The num-
ber of positive aPL antibodies detected in the various patient groups
is shown in Table 4. Only ten of the total cohort of 211 patients were
positive for all four criteria-deﬁned aPLs. All ten were APS patients.
Triple positivity for APL antibodies was found in 4 patients with
APS, one patient with SLE, and none in any of the other clincial
groups. Patients with three positive criteria-deﬁned aPLs were
more often observed in APS patients (4/61:7%) compared with the
other groups (1/37:3%) in lupus patients and none in the other
groups. Similarly the frequency of APS patients with two positive
criteria-deﬁned aPLs was higher (22/61:44%) than the in incidence
observed in the other groups (2/37(6%) for lupus, 1/53 for non-
lupus autoimmune disease, 0/34 for hepatitis and 0/10 among the
healthy controls). Patients with multiple-positive aPLs were more
often observed in the APS group (47/61: 77%) compared with the
other groups (lupus 3/37, non-SLE CTD 1/53, non-autoimmune 1/
16, hepatitis 0/34, healthy 0/10; p b 0.0000001 Kruskal-Wallis test).4. Discussion
The current ﬁndings conﬁrm that the utility of the APL panel was
similar to conventional ELISA methods. Past reports suggested that IgG
tests (aCL, aβ2GPI) show higher sensitivity for the diagnosis of APS,
while IgM assays show higher speciﬁcity and this was also observed in
the current ﬁndings. There are recent reports that analyzed IgG/M aCL
and aβ2GPI with the APL CIA panel in primary APS compared with the
non-APS control patients with APS manifestations (thrombosis and/or
pregnancy morbidity) [14,15]. The studies analyzed the sensitivity and
speciﬁcity of each aPLs individually and reported that the APL CIA
panel has similar sensitivities and speciﬁcities to the comparable ELISA
tests. In this report, the sensitivities and speciﬁcities of each CIA panel
tests compared with the past two reports, had mild to moderate dis-
crepancies possibly due to the different backgrounds of the patient
cohorts.
The present study is the ﬁrst to analyze the signiﬁcance of the CIA
panel in the real-life setting of patients with autoimmune diseases in
the rheumatology clinic. Also, it is the ﬁrst to clarify the signiﬁcance of
multiple-positivity determinations using an automated instrument for
the diagnosis of APS. Additionally, a wide variety of control groups (37
SLE, 53 non-SLE CTD patients and 16 non-CTD patients with resembling
manifestations) were included in our study, adding signiﬁcant robust-
ness to the speciﬁcity analysis.
Table 1
Results of measurement of patients with antiphospholipid antibody syndrome using the APL CIA panel.
Sensitivity %
(95%CI)
Speciﬁcity %
(95%CI)
PLR
(95%CI)
NLR
(95%CI)
OR
(95%CI)
Class
(95%CI)
A Testing with current criteria assays only (IgA and aβ2GPI D1 assays excluded)
aCL IgG 68.3
(55.0–79.7)
93.7
(88.4–97.1)
10.9
(5.8–20.8)
0.34
(0.23–0.47)
32.1
(13.6–75.8)
0.86
(0.82–0.91)
aβ2GPI IgG 75.0
(62.1–85.3)
90.2
(84.1–94.5)
7.7
(4.61–12.9)
0.28
(0.17–0.41)
27.6
(12.4–61.5)
0.86
(0.82–0.91)
aCL IgM 25.0
(14.7–37.9)
97.9
(94.0–99.6)
11.9
(3.8–37.4)
0.77
(0.64–0.86)
15.6
(4.6–52.5)
0.76
(0.70–0.82)
aβ2GPI IgM 28.3
(17.5–41.4)
99.3
(96.2–100.0)
40.5
(7.1–236.0)
0.72
(0.60–0.82)
56.1
(9.1–339)
0.78
(0.72–0.84)
Positive for any item 84.0
(64.6–94.1)
90.1
(82.0–94.9)
8.49
(4.46–16.2)
0.18
(0.07–0.44)
47.83
(14.2–161)
0.88
(0.83–0.95)
Positive for the second and subsequent items 67.2%
(54.3–77.9)
93.4%
(87.8–96.6)
10.24 (5.31–19.7) 0.35
(0.24–0.51)
29.2
(12.4–68.5)
0.86
(0.81–0.91)
Positive for the third and subsequent items 20.7%
(12.2–33.0)
99.3%
(95.5–100)
28.3
(3.77–213)
0.80
(0.70–0.91)
35.5
(6.32–199)
0.76
(0.70–0.82)
Positive for the fourth item 17.2%
(9.5–29.2)
100%
(96.6–100)
0.83
(0.74–0.93)
0.75
(0.69–0.81)
B Testing by criteria assays and IgA aCL, IgA aβ2GPI, and aβ2GPI D1
aCL IgG 68.3
(55.0–79.7)
93.7
(88.4–97.1)
10.9
(5.8–20.8)
0.34
(0.23–0.47)
32.1
(13.6–75.8)
0.86
(0.82–0.91)
aβ2GPI IgG 75.0
(62.1–85.3)
90.2
(84.1–94.5)
7.7
(4.61–12.9)
0.28
(0.17–0.41)
27.6
(12.4–61.5)
0.86
(0.82–0.91)
aCL IgM 25.0
(14.7–37.9)
97.9
(94.0–99.6)
11.9
(3.8–37.4)
0.77
(0.64–0.86)
15.6
(4.6–52.5)
0.76
(0.70–0.82)
aβ2GPI IgM 28.3
(17.5–41.4)
99.3
(96.2–100.0)
40.5
(7.1–236.0)
0.72
(0.60–0.82)
56.1
(9.1–339.4)
0.78
(0.72–0.84)
aCL IgA 26.2
(16.8–38.6)
96.7
(92.2–98.9)
7.92
(3.04–20.7)
0.76
(0.66–0.89)
10.4
(3.74–18.8)
0.76
(0.71–0.82)
aβ2GPI IgA 27.9
(18.2–40.3)
96.7
(92.2–98.8)
8.42
(3.25–21.8)
0.75
(0.64–0.87)
11.3
(4.09–31.4)
0.77
(0.71–0.83)
aβ2GPI D1 52.5
(40.0–64.7)
100
(96.9–100)
0.48
(0.36–0.62)
86.7
(82.1–91.3)
Positive for any item 84.0
(64.6–94.1)
90.1
(82.0–94.9)
8.49
(4.46–16.2)
0.18
(0.072–0.44)
47.83
(14.2–161)
0.88
(0.83–0.95)
Positive for the second and subsequent items 67.2%
(54.3–77.9)
93.4%
(87.8–96.6)
10.24
(5.31–19.7)
0.35
(0.24–0.51)
29.2
(12.4–68.5)
0.86
(0.81–0.91)
Positive for the third and subsequent items 20.7%
(12.2–33.0)
99.3%
(95.5–100)
28.3
(3.77–213)
0.80
(0.70–0.91)
35.5
(6.32–199.3)
0.76
(0.70–0.82)
Positive for the fourth and subsequent items 17.2%
(9.5–29.2)
100%
(96.6–100)
0.83
(0.74–0.93)
0.75
(0.69–0.81)
Positive for the ﬁfth and subsequent items 17.2%
(9.5–29.2)
100%
(96.6–100)
0.83
(0.74–0.93)
0.75
(0.69–0.81)
Positive for the sixth and subsequent items 11.5%
(5.4–22.2)
100%
(96.9–100)
0.89
(0.81–0.97)
0.75
(0.69–0.80)
Positive for the seventh and subsequent items 11.5%
(5.4–22.2)
100%
(96.9–100)
0.89
(0.81–0.97)
0.75
(0.69–0.80)
aCL: anticardiolipin antibody, aβ2GPI: antiβ2GPI antibody, PLR: positive likelihood ratio, NLR: negative likelihood ratio, OR: odds ratio, 95%CI: 95% conﬁdence interval, class: probability of
correct classiﬁcation.
Table 2
Results of measurement of patients with antiphospholipid antibody syndrome using homemade ELISAs.
Measurement Sensitivity (%)
(95%CI)
Speciﬁcity (%)
(95%CI)
PLR
(95%CI)
NLR
(95%CI)
OR
(95%CI)
Class
(95%CI)
aCL IgG 71.9
(59.0–81.9)
92.2
(85.1–96.2)
9.26
(4.67–18.4)
0.30
(0.20–0.46)
30.4
(12.3–75.2)
0.85
(0.80–0.91)
aβ2GPI IgG 62.5
(42.6–78.8)
94.3
(86.8–97.8)
10.88
(4.40–26.9)
0.40
(0.24–0.67)
27.3
(8.38–89.1)
0.87
(0.81–0.94)
aCL IgM 22.0
(13.3–34.3)
100.0
(95.6–100.0)
0.78
(0.68–0.89)
0.72
(0.65–0.79)
aβ2GPI IgM 21.7
(9.4–42.5)
97.8
(91.7–99.8)
9.78
(2.03–47.2)
0.80
(0.64–1.00)
12.2
(2.53–59.2)
0.82
(0.75–0.89)
Positive for any item 95.5
(76.2–100)
90.1
(82.0–94.9)
9.65
(5.16–18.1)
0.05
(0.01–0.34)
191.3
(32.07–1142)
0.91
(0.86–0.96)
Positive for second and subsequent items 68.2%
(47.1–83.7)
90.8%
(83.2–95.2)
7.42
(3.74–14.7)
0.35
(0.19–0.65)
21.2
(7.06–18.2)
0.87
(0.81–0.93)
Positive for third and subsequent items 31.8%
(16.3–52.9)
92.9%
(85.7–96.7)
4.46
(1.74–11.4)
0.73
(0.55–0.98)
6.07
(1.93–19.1)
0.82
(0.75–0.89)
Positive for fourth item 4.3%
(0.0–23.0)
100%
(95.0–100)
0.96
(0.88–1.04)
0.81
(0.73–0.88)
aCL: anticardiolipin antibody, aβ2GPI: anti-β2GPI antibody, PLR: positive likelihood ratio, NLR: negative likelihood ratio, OR: odds ratio, 95%CI: 95% conﬁdence interval class: probability of
correct classiﬁcation.
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Table 3
The concordance rates of aPL detections between ELISAs and the APL CIA panel.
aCL IgG aCL IgM aβ2GPI IgG aβ2GPI IgM
Kappa value
(95% CI)
0.657
(0.509–0.768)
0.562
(0.327–0.744)
0.591
(0.224–0.724)
0.558
(0.321–0.741)
Kappa value: Cohen's kappavalue, 95% CI: 95% conﬁdence interval, aCL: anticardiolipin an-
tibody, aβ2GPI: anti-β2GPI antibody.
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tients were negative for both aCL and aβ2GPI aPLs respectively using
both the APL CIA panel and the homemade ELISAs. In general, the pro-
portion of APS patients who are diagnosed with lupus anticoagulant
alone varies from 20 to 40%, but the proportion was comparatively
low in our cohort.
We investigated non-criteria aPLs in our study that are IgA aPLs (aCL
IgA and aβ2GPI IgA) and aβ2GPI DI antibody. The signiﬁcance of IgA aPLs
remains controversial, however, there are several reports showing the
moderate sensitivities of the antibodies or high hazard ratio for APS
[16] [17].
In our study, IgA aPLs had high speciﬁcities while their sensitivities
remain low comparable to IgM antibodies (aCl IgM and aβ2GPI IgM)
in accordancewith the past reports. Moreover, in all cases with positive
IgA antibodies, more than one criteria-deﬁned aPLswere positive. Thus,
these antibodies may have less contribution to the screening of APS,
however, they possibly are beneﬁcial for conﬁrmation of the diagnosis.
Although aβ2GPI D1 antibody was positive in just over half (52.5%)
of the APS patients, it was 100% speciﬁc for APS. While most of the pos-
itive aβ2GPI D1 caseswere positive for aβ2GPI IgG, 2/31 cases were neg-
ative for aβ2GPI IgG, including 1 case that was negative for all other aPLs
that were examined in this study. The antibody values for aβ2GPI D1 in
these 2 cases were 47.1 and 51.7 U/ml, respectively, which were higher
than the ULN value. Anti-β2GPI D1 functions as a conﬁrmatory test with
its high speciﬁcity andmay detect autoantibodies that cannot be detect-
ed by conventional aβ2GPI measurement methods.Table 4
Number of positive cases in individual groups when tested with the APL CIA panel.
Positive tests APS SLE CTD
A. Criteria assays only (IgA and aβ2GPI D1 assays excluded)
0 8
(13%)
31
(84%)
45
(85%)
1 12
(20%)
3
(8%)
7
(13%)
2 27
(44%)
2
(6%)
1
(2%)
3 4
(7%)
1
(3%)
0
4 10
(16%)
0 0
Total 61 37 53
B. Testing by criteria assays and IgA aCL, IgA aβ2GPI, and aβ2GPI D1
0 7
(11%)
30
(81%)
43
(81%)
1 12
(20%)
3
(8%)
7
(13%)
2 6
(10%)
3
(8%)
2
(4%)
3 15
(25%)
0
(0%)
1
(2%)
4 5
(8%)
0 0
5 9
(15%)
1
(3%)
0
6 0
(0%)
0 0
7 7
(11%)
0 0
Total 61 37 53Lupus anticoagulant is recognized as sensitive and speciﬁc for the di-
agnosis of APS, however it is technically very demanding to performand
there are many unclear factors that signiﬁcantly inﬂuence its reliable
measurement. Recently, it has been determined that prothrombin is a
major target of lupus anticoagulant in addition toβ2GPI. It has been sug-
gested that phosphatidylserine-dependent anti-prothrombin antibody
(aPS/PT) should be considered as a speciﬁc criteria marker of APS
along with aCL and aβ2GPI. Furthermore, it has also been suggested
that these 3 antibodies (aCL, aβ2GPI and aPS/PT) might be more useful
overall than the lupus anticoagulant test [18]. At present PSPT is not
available on the BIO-FLASH/ACL Acustar platform however, so its inclu-
sion in any aPL test panel will need to utilize results obtained from tests
in ELISA format. In the APS patient cohort examined in our study, a sin-
gle positive case with 4 individual aPLs that were measured with APL
CIA panel, was conﬁrmed. Furthermore, it was found that the sensitivity
and probability for the correct classiﬁcation of APS diagnosis was higher
when all 4 types of aPL were examined, compared with testing for only
3 types. Indeed, in the testwith theAPL CIA panel, theproportion of pos-
itive aPLs in the APS group was higher than in the other groups. These
ﬁndings have already been suggested in past reports, and various
types of aPL with high titer are easily expressed in APS patients, com-
pared to patients with connective tissue diseases who are positive for
aPL and those who temporarily express aPL occur readily caused easily
in such APS patients [19].
Based on these observations, many examinations have been per-
formed to quantitatively assess the antibody value of aPLs. We deﬁned
antiphospholipid antibody scores through formula manipulation for
the measured hazard ratios of individual aPLs and antibody values for
thrombosis, using the aPL data from patients with connective tissue dis-
eases, including the APS patients. It was clearly shown that when an ap-
propriate cutoff value was set, the scores would signiﬁcantly contribute
to accurate APS diagnosis, with higher sensitivity and speciﬁcity, com-
pared with the conventional APS classiﬁcation criteria, and that high
scores would represent an extremely high risk of future development
of thrombosis in patients with connective tissue diseases [20]. ThisNon-autoimmune Hepatitis Healthy
13
(81%)
29
(85%)
10
(100%)
2
(13%)
5
(15%)
0
1
(6%)
0 0
0 0 0
0 0 0
16 34 10
13
(81%)
29
(85%)
10
(100%)
2
(13%)
4
(12%)
0
1
(6%)
0 0
0 1
(3%)
0
0 0 0
0 0 0
0 0 0
0 0 0
16 34 10
6 K. Oku et al. / Thrombosis Research 146 (2016) 1–6score has been validated at other facilities [13,21]. The APL score is cal-
culated by measuring 14 types of aPL. It was conﬁrmed that measure-
ment of fewer aPL would also contribute to APS diagnosis and the
prediction of thrombosis (modiﬁed aPL score) [13]. It was also deter-
mined that examinations utilizing aPSPT, aCL, and aβ2GPI would exhibit
higher diagnostic capability than the present classiﬁcation criteria.
5. Conclusion
The chemiluminescent assays (CIA) evaluated multiple aPLs simul-
taneously with equivalent accuracy to the classical ELISA. In our cohort,
two or more aPLs were speciﬁcally found in APS patients, reinforcing
that the multiple aPLs analysis is essential in APS diagnosis and CIA is
a labor-saving technique that readily analyze multiple tests
automatically.
In the future, there remains a strong possibility that concomitant use
of automated measurement of aPL and a quantitative evaluation tool
assessing antibody value, i.e., including the antiphospholipid antibody
score, could contribute to higher diagnostic detection of APS and im-
proved prediction capability for thrombosis.
Acknowledgement
Disclosures: Gary L. Norman is an employee of InovaDiagnostics, Inc.
This work was the result of the contract research activities between
IL Japan (Tokyo, Japan) and Department of Rheumatology, Endocrinolo-
gy and Nephrology, Hokkaido University Graduate School of Medicine.
References
[1] A. Ruffatti, T. Del Ross, M. Ciprian, et al., Risk factors for a ﬁrst thrombotic event in
antiphospholipid antibody carriers. A multicentre, retrospective follow-up study,
Ann. Rheum. Dis. 68 (3) (2009) 397–399.
[2] S. Miyakis, M.D. Lockshin, T. Atsumi, et al., International consensus statement on an
update of the classiﬁcation criteria for deﬁnite antiphospholipid syndrome (APS), J.
Thromb. Haemost. 4 (2) (2006) 295–306.
[3] H. Meijide, S. Sciascia, G. Sanna, et al., The clinical relevance of IgA anticardiolipin
and IgA anti-beta2 glycoprotein I antiphospholipid antibodies: a systematic review,
Autoimmun. Rev. 12 (3) (2013) 421–425.
[4] B. de Laat, X.X.Wu, M. van Lummel, et al., Correlation between antiphospholipid an-
tibodies that recognize domain I of beta2-glycoprotein I and a reduction in the an-
ticoagulant activity of annexin A5, Blood 109 (4) (2007) 1490–1494.[5] E. de Maistre, F. Volot, G. Mourey, et al., Performance of two new automated assays
for measuring von Willebrand activity: HemosIL AcuStar and Innovance, Thromb.
Haemost. 112 (4) (2014) 825–830.
[6] G. Lippi, L. Ippolito, T. Russello, et al., Analytical performance of the new ACL AcuStar
HemosIL D-Dimer, Blood Coagul. Fibrinolysis 23 (2) (2012) 164–167.
[7] V. Minet, N. Bailly, J. Douxﬁls, et al., Assessment of the performances of AcuStar HIT
and the combination with heparin-induced multiple electrode aggregometry: a ret-
rospective study, Thromb. Res. 132 (3) (2013) 352–359.
[8] N. Abdel-Wahab, M.A. Lopez-Olivo, G.P. Pinto-Patarroyo, et al., Systematic review of
case reports of antiphospholipid syndrome following infection, Lupus (2016).
[9] P. Ambrosino, R. Lupoli, P. Tarantino, et al., Viral hepatitis and anti-phospholipid an-
tibodies positivity: a systematic review and meta-analysis, Dig. Liver Dis. 47 (6)
(2015) 478–487.
[10] C. Palazzi, D. Buskila, S. D'Angelo, et al., Autoantibodies in patients with chronic hep-
atitis C virus infection: pitfalls for the diagnosis of rheumatic diseases, Autoimmun.
Rev. 11 (9) (2012) 659–663.
[11] E.N. Harris, A.E. Gharavi, S.P. Patel, et al., Evaluation of the anti-cardiolipin antibody
test: report of an international workshop held 4 April 1986, Clin. Exp. Immunol. 68
(1) (1987) 215–222.
[12] O. Amengual, T. Atsumi, M.A. Khamashta, et al., Speciﬁcity of ELISA for antibody to
beta 2-glycoprotein I in patients with antiphospholipid syndrome, Br. J. Rheumatol.
35 (12) (1996) 1239–1243.
[13] K. Otomo, T. Atsumi, O. Amengual, et al., Efﬁcacy of the antiphospholipid score for
the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic
events, Arthritis Rheum. 64 (2) (2012) 504–512.
[14] L. Meneghel, A. Ruffatti, S. Gavasso, et al., The clinical performance of a chemilumi-
nescent immunoassay in detecting anti-cardiolipin and anti-beta2 glycoprotein I an-
tibodies. A comparison with a homemade ELISA method, Clin. Chem. Lab. Med.
(2015).
[15] S. Zhang, Z.Wu, P. Li, F. Zhang, Y. Li, Evaluation of the clinical performance of a novel
chemiluminescent immunoassay for detection of anticardiolipin and anti-beta2-gly-
coprotein 1 antibodies in the diagnosis of antiphospholipid syndrome, Medicine
(Baltimore) 94 (46) (2015), e2059.
[16] C. Pericleous, I. Ferreira, O. Borghi, et al., Measuring IgA anti-beta2-glycoprotein I
and IgG/IgA anti-domain I antibodies adds value to current serological assays for
the antiphospholipid syndrome, PLoS One 11 (6) (2016), e0156407.
[17] M. Ciesla, E. Wypasek, A. Undas, IgA antiphospholipid antibodies and anti-domain 1
of beta 2 glycoprotein 1 antibodies are associated with livedo reticularis and heart
valve disease in antiphospholipid syndrome, Adv. Clin. Exp. Med. 23 (5) (2014)
729–733.
[18] K. Oku, T. Atsumi, O. Amengual, et al., Antiprothrombin antibody testing: detection
and clinical utility, Semin. Thromb. Hemost. 34 (4) (2008) 335–339.
[19] G. Hernandez-Molina, G. Espericueta-Arriola, A.R. Cabral, The role of lupus anticoag-
ulant and triple marker positivity as risk factors for rethrombosis in patients with
primary antiphospholipid syndrome, Clin. Exp. Rheumatol. 31 (3) (2013) 382–388.
[20] K. Oku, O. Amengual, T. Atsumi, Antiphospholipid scoring: signiﬁcance in diagnosis
and prognosis, Lupus 23 (12) (2014) 1269–1272.
[21] S. Sciascia, M.L. Bertolaccini, D. Roccatello, et al., Independent validation of the
antiphospholipid score for the diagnosis of antiphospholipid syndrome, Ann.
Rheum. Dis. 72 (1) (2013) 142–143.
